Outcomes After Listing for Liver Transplant in Patients With Acute-on-Chronic Liver Failure: The Multicenter North American Consortium for the Study of End-Stage Liver Disease Experience.
Acute Kidney Injury
/ epidemiology
Acute-On-Chronic Liver Failure
/ epidemiology
Adult
Disease Progression
End Stage Liver Disease
/ complications
Female
Hospital Mortality
Hospitalization
/ statistics & numerical data
Humans
Liver Cirrhosis
/ complications
Liver Transplantation
Male
Middle Aged
North America
/ epidemiology
Prospective Studies
Renal Dialysis
/ statistics & numerical data
Severity of Illness Index
Survival Rate
Time-to-Treatment
Waiting Lists
/ mortality
Journal
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
ISSN: 1527-6473
Titre abrégé: Liver Transpl
Pays: United States
ID NLM: 100909185
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
received:
15
09
2018
accepted:
08
01
2019
pubmed:
7
2
2019
medline:
6
5
2020
entrez:
7
2
2019
Statut:
ppublish
Résumé
Acute-on-chronic liver failure (ACLF) characterized with ≥2 extrahepatic organ failures in cirrhosis carries a high mortality. Outcomes of patients listed for liver transplantation (LT) after ACLF and after LT are largely unknown. The North American Consortium for the Study of End-Stage Liver Disease prospectively enrolled 2793 nonelectively hospitalized patients with cirrhosis; 768 were listed for LT. Within 3 months, 265 (35%) received a LT, 395 remained alive without LT, and 108 died/delisted. Compared with nonlisted patients, those listed were younger and more often had ACLF, acute kidney injury, and a higher admission Model for End-Stage Liver Disease (MELD) score. ACLF was most common in patients who died/delisted, followed by those alive with and without LT respectively, (30%, 22%, and 7%, respectively; P < 0.001). At LT, median MELD was 27.9% and 70% were inpatients; median time from hospitalization to LT was 26 days. Post-LT survival at 6 months was unchanged between those with and without ACLF (93% each at 6 months). There was no difference in 3- and 6-month mean post-LT creatinine in those with and without ACLF, despite those with ACLF having a higher mean pre-LT creatinine and a higher rate of perioperative dialysis (61%). In conclusion, patients with and without ACLF had similar survival after transplant with excellent renal recovery in both groups.
Types de publication
Comparative Study
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
571-579Informations de copyright
Copyright © 2019 by the American Association for the Study of Liver Diseases.